Overview:

Summary

Global Markets Direct’s, 'Birch Pollen Allergy - Pipeline Review, Q2 2011', provides an overview of the Birch Pollen Allergy therapeutic pipeline. This report provides information on the therapeutic development for Birch Pollen Allergy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Birch Pollen Allergy. 'Birch Pollen Allergy - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Birch Pollen Allergy.
- A review of the Birch Pollen Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Birch Pollen Allergy pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Birch Pollen Allergy.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Birch Pollen Allergy pipeline depth and focus of Birch Pollen Allergy therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Birch Pollen Allergy Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Birch Pollen Allergy 8
Birch Pollen Allergy Therapeutics under Development by Companies 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Discovery and Pre-Clinical Stage Products 14
Comparative Analysis 14
Birch Pollen Allergy Therapeutics - Products under Development by Companies 15
Companies Involved in Birch Pollen Allergy Therapeutics Development 16
ALK-Abello A/S 16
Allergy Therapeutics plc 16
Paladin Labs Inc. 17
Stallergenes S.A. 17
Allergopharma Joachim Ganzer KG 18
ImVisioN Therapeutics AG 18
Biomay AG 19
Birch Pollen Allergy - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Late Stage Drug Profiles 25
rBet v1 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Birch Pollen Allergoid - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
AL0206st - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
ALK Birch Pollen Vaccine - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
IVN-Birch - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
TreeMATA MPL - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Recombinant Birch Pollen Allergen - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Staller - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Birch Pollen Allergen B-Cell Peptide Vaccine - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Birch Allergen RNA Vaccine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Birch Pollen Allergy - Featured News 37
Apr 26, 2011: FDA To Lift Allergy Therapeutics INDs Clinical Hold For Three MATA-MPL Products 37
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 39
Contact Us 39
Disclaimer 39"

List of Tables
Number of Products Under Development for Birch Pollen Allergy, Q2 2011 8
Products under Development for Birch Pollen Allergy – Comparative Analysis, Q2 2011 9
Number of Products under Development by Companies, Q2 2011 10
Comparative Analysis by Late Stage Development, Q2 2011 11
Comparative Analysis by Mid Clinical Stage Development, Q2 2011 12
Comparative Analysis by Early Clinical Stage Development, Q2 2011 13
Comparative Analysis by Discovery and Pre-Clinical Stage Development, Q2 2011 14
Products under Development by Companies, Q2 2011 15
ALK-Abello A/S, 2011 16
Allergy Therapeutics plc, 2011 16
Paladin Labs Inc., 2011 17
Stallergenes S.A., 2011 17
Allergopharma Joachim Ganzer KG, 2011 18
ImVisioN Therapeutics AG, 2011 18
Biomay AG, 2011 19
Assessment by Monotherapy Products, Q2 2011 20
Assessment by Stage and Route of Administration, Q2 2011 22
Assessment by Molecule Type, Q2 2011 24"

List of Figures
Number of Products under Development for Birch Pollen Allergy, Q2 2011 8
Products under Development for Birch Pollen Allergy – Comparative Analysis, Q2 2011 9
Products under Development by Companies, Q2 2011 10
Late Stage Products, Q2 2011 11
Mid Clinical Stage Products, Q2 2011 12
Early Clinical Stage Products, Q2 2011 13
Discovery and Pre-Clinical Stage Products, Q2 2011 14
Assessment by Monotherapy Products, Q2 2011 20
Assessment by Route of Administration, Q2 2011 21
Assessment by Stage and Route of Administration, Q2 2011 22
Assessment by Molecule Type, Q2 2011 23
Assessment by Stage and Molecule Type, Q2 2011 24